CY1117794T1 - Διαλυμα για χορηγηση απο το στομα - Google Patents
Διαλυμα για χορηγηση απο το στομαInfo
- Publication number
- CY1117794T1 CY1117794T1 CY20161100695T CY161100695T CY1117794T1 CY 1117794 T1 CY1117794 T1 CY 1117794T1 CY 20161100695 T CY20161100695 T CY 20161100695T CY 161100695 T CY161100695 T CY 161100695T CY 1117794 T1 CY1117794 T1 CY 1117794T1
- Authority
- CY
- Cyprus
- Prior art keywords
- acid
- oral administration
- solution
- compound
- salt
- Prior art date
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract 1
- 235000011054 acetic acid Nutrition 0.000 abstract 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 abstract 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract 1
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 abstract 1
- 235000015165 citric acid Nutrition 0.000 abstract 1
- 239000004310 lactic acid Substances 0.000 abstract 1
- 235000014655 lactic acid Nutrition 0.000 abstract 1
- 239000001630 malic acid Substances 0.000 abstract 1
- 235000011090 malic acid Nutrition 0.000 abstract 1
- 229940100688 oral solution Drugs 0.000 abstract 1
- 239000001384 succinic acid Substances 0.000 abstract 1
- 235000011044 succinic acid Nutrition 0.000 abstract 1
- 239000011975 tartaric acid Substances 0.000 abstract 1
- 235000002906 tartaric acid Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161548859P | 2011-10-19 | 2011-10-19 | |
| PCT/JP2012/077668 WO2013058411A1 (en) | 2011-10-19 | 2012-10-19 | Solution for oral administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1117794T1 true CY1117794T1 (el) | 2017-05-17 |
Family
ID=47178263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161100695T CY1117794T1 (el) | 2011-10-19 | 2016-07-18 | Διαλυμα για χορηγηση απο το στομα |
Country Status (35)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| JP6203682B2 (ja) * | 2013-07-10 | 2017-09-27 | 共和薬品工業株式会社 | アリピプラゾール含有水性液剤 |
| UA124498C2 (uk) * | 2015-12-01 | 2021-09-29 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Фармацевтична композиція для лікування інфекційно-запальних захворювань місцевого застосування і спосіб її одержання та застосування (варіанти) |
| RU2633635C1 (ru) * | 2016-06-29 | 2017-10-16 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения |
| WO2017095265A1 (ru) * | 2015-12-01 | 2017-06-08 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения |
| RU2627423C1 (ru) * | 2016-06-29 | 2017-08-08 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения |
| JP6786240B2 (ja) * | 2016-03-31 | 2020-11-18 | 小林製薬株式会社 | 粘性経口組成物 |
| WO2019075127A1 (en) * | 2017-10-10 | 2019-04-18 | Vertice Pharma, Llc | ORAL MICODRIN HYDROCHLORIDE SOLUTION AND USES THEREOF |
| WO2021029020A1 (ja) * | 2019-08-13 | 2021-02-18 | 大塚製薬株式会社 | 経口医薬組成物 |
| JP2021115288A (ja) * | 2020-01-28 | 2021-08-10 | 青葉化成株式会社 | 液状組成物および液状医療材料 |
| CA3184420A1 (en) | 2020-06-30 | 2022-01-06 | Mark C. Faulkner | Compositions and methods for treatment of vaginal infections |
| EP4171513A4 (en) * | 2020-06-30 | 2024-07-17 | VIREO Systems, Inc. | COMPOSITIONS FOR ODOUR AND ITCHING CONTROL AND METHODS AND DEVICES FOR THEIR ADMINISTRATION |
| WO2022218356A1 (zh) * | 2021-04-13 | 2022-10-20 | 上海博志研新药物技术有限公司 | 一种布瑞哌唑口溶膜组合物、其制备方法及应用 |
| CN115414322A (zh) * | 2022-07-05 | 2022-12-02 | 杭州民生药物研究院有限公司 | 一种富马酸卢帕他定口服液体制剂及其制备工艺 |
| CN116966140A (zh) * | 2023-08-18 | 2023-10-31 | 四川阿赛斯生物科技有限公司 | 一种含有布瑞哌唑的口服溶液及其制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1420077A (en) * | 1972-04-14 | 1976-01-07 | Unilever Ltd | Process for imparting or enhancing fresh cheese flavour in a food digital transmission systems |
| MY129350A (en) * | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
| KR101027570B1 (ko) * | 2002-05-03 | 2011-04-06 | 이스라엘 인스티튜트 포 바이올로지컬 리서치 | 중추 및 말초 신경계 장애의 치료를 위한 방법 및 조성물, 및 그에 유용한 신규 화합물 |
| US20080032384A1 (en) * | 2004-04-22 | 2008-02-07 | Takehiko Nomura | Pharmaceutical Preparation Containing Bacterial Cell Wall Skeleton |
| JP4315393B2 (ja) * | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
| TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| ES2390353T3 (es) * | 2005-06-13 | 2012-11-12 | Dainippon Sumitomo Pharma Co., Ltd. | Preparación de disolución |
| PT1948133E (pt) * | 2005-09-01 | 2011-08-01 | Baxter Healthcare Sa | Formulação de argatroban que compreende um ácido como solubilizante |
| WO2008016165A2 (en) * | 2006-07-31 | 2008-02-07 | Asubio Pharma Co., Ltd. | Liquid preparation |
| KR20100072253A (ko) * | 2007-09-17 | 2010-06-30 | 쉐링 코포레이션 | 사이클린-의존성 키나제 억제 화합물을 함유하는 제형 및 이를 사용한 종양의 치료방법 |
| JP2010540448A (ja) * | 2007-09-21 | 2010-12-24 | フォレスト・ラボラトリーズ・ホールディングス・リミテッド | 非経口投与に適したセフェム誘導体を含む可溶製剤 |
| US8263652B2 (en) * | 2007-10-31 | 2012-09-11 | Sk Biopharmaceuticals Co., Ltd. | Stabilized pediatric suspension of carisbamate |
| RU2535089C2 (ru) * | 2010-08-24 | 2014-12-10 | Оцука Фармасьютикал Ко., Лтд. | Суспензия и затвердевшая композиция, содержащие производное карбостирила и силиконовое масло и/или производное силиконового масла |
| CN102119922A (zh) * | 2011-03-03 | 2011-07-13 | 天津市炜杰科技有限公司 | 以酸作为增溶剂的21(s)阿加曲班静脉注射液 |
| JOP20120083B1 (ar) * | 2011-04-05 | 2021-08-17 | Otsuka Pharma Co Ltd | توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns |
-
2012
- 2012-10-18 TW TW106124366A patent/TWI679977B/zh active
- 2012-10-18 TW TW101138422A patent/TWI632921B/zh active
- 2012-10-18 JO JOP/2012/0316A patent/JO3190B1/ar active
- 2012-10-18 AR ARP120103877A patent/AR088372A1/es not_active Application Discontinuation
- 2012-10-19 PT PT127847531T patent/PT2768508T/pt unknown
- 2012-10-19 SI SI201230656A patent/SI2768508T1/sl unknown
- 2012-10-19 WO PCT/JP2012/077668 patent/WO2013058411A1/en not_active Ceased
- 2012-10-19 BR BR112014009330A patent/BR112014009330A2/pt not_active Application Discontinuation
- 2012-10-19 US US14/352,479 patent/US20140303183A1/en not_active Abandoned
- 2012-10-19 PH PH1/2014/500816A patent/PH12014500816A1/en unknown
- 2012-10-19 CA CA2851999A patent/CA2851999C/en active Active
- 2012-10-19 DK DK12784753.1T patent/DK2768508T3/en active
- 2012-10-19 CN CN201711285346.0A patent/CN107823131A/zh active Pending
- 2012-10-19 ME MEP-2016-143A patent/ME02459B/me unknown
- 2012-10-19 LT LTEP12784753.1T patent/LT2768508T/lt unknown
- 2012-10-19 EA EA202190445A patent/EA202190445A2/ru unknown
- 2012-10-19 EA EA201490812A patent/EA201490812A1/ru unknown
- 2012-10-19 EP EP12784753.1A patent/EP2768508B1/en active Active
- 2012-10-19 HR HRP20160989TT patent/HRP20160989T1/hr unknown
- 2012-10-19 MX MX2014004529A patent/MX347309B/es active IP Right Grant
- 2012-10-19 CN CN201280051524.2A patent/CN103889426A/zh active Pending
- 2012-10-19 SG SG11201401273SA patent/SG11201401273SA/en unknown
- 2012-10-19 UA UAA201405162A patent/UA111506C2/uk unknown
- 2012-10-19 HU HUE12784753A patent/HUE028869T2/en unknown
- 2012-10-19 ES ES12784753.1T patent/ES2583137T3/es active Active
- 2012-10-19 MY MYPI2014700955A patent/MY169096A/en unknown
- 2012-10-19 KR KR1020147013277A patent/KR101856283B1/ko active Active
- 2012-10-19 JP JP2014517060A patent/JP6077534B2/ja active Active
- 2012-10-19 RS RS20160549A patent/RS54967B1/sr unknown
- 2012-10-19 AU AU2012326978A patent/AU2012326978B2/en active Active
- 2012-10-19 PL PL12784753.1T patent/PL2768508T3/pl unknown
-
2014
- 2014-04-07 IL IL231988A patent/IL231988A/en active IP Right Grant
- 2014-04-11 ZA ZA2014/02669A patent/ZA201402669B/en unknown
- 2014-04-15 IN IN2987DEN2014 patent/IN2014DN02987A/en unknown
- 2014-04-15 CL CL2014000967A patent/CL2014000967A1/es unknown
- 2014-05-13 CO CO14102721A patent/CO6950486A2/es unknown
-
2016
- 2016-01-21 US US15/003,347 patent/US20160213665A1/en not_active Abandoned
- 2016-07-18 CY CY20161100695T patent/CY1117794T1/el unknown
- 2016-09-29 SM SM201600341T patent/SMT201600341B/it unknown
-
2017
- 2017-02-24 US US15/441,881 patent/US20170182036A1/en not_active Abandoned
- 2017-08-11 AU AU2017213570A patent/AU2017213570A1/en not_active Abandoned
-
2018
- 2018-05-25 US US15/989,294 patent/US20180271858A1/en not_active Abandoned
-
2019
- 2019-09-10 US US16/566,178 patent/US20200171023A1/en not_active Abandoned
-
2020
- 2020-11-13 US US17/097,168 patent/US20210236483A1/en not_active Abandoned
-
2023
- 2023-03-27 US US18/190,839 patent/US20240009186A1/en not_active Abandoned
-
2024
- 2024-08-01 US US18/791,730 patent/US20250099460A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1117794T1 (el) | Διαλυμα για χορηγηση απο το στομα | |
| SG178952A1 (en) | Chemical compounds | |
| BR112015014678A2 (pt) | lactamas fundidas com arila e heteroarila | |
| PH12012502569A1 (en) | Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts | |
| CY1113963T1 (el) | Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος | |
| NO20076635L (no) | Krystallinske og andre former for 4-amino-5-fluor-3-[6-(4-metylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-kinolin-2-on-melkesyresalter | |
| BR112015000704A2 (pt) | imidazotriazinacarbonitrilas úteis como inibidores de quinase | |
| CO6480927A2 (es) | Derivados de imidazolin-2-ona 1,3-disustituida como inhibidores de cyp17. | |
| TN2009000180A1 (en) | NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF | |
| MX2021008356A (es) | Inhibidores de jak2 y alk2 y metodos para su uso. | |
| EA201390885A1 (ru) | Азаиндолы в качестве противовирусных агентов против респираторного синцитиального вируса | |
| NZ602544A (en) | Crystalline forms of a macrolide, and uses therefor | |
| EA201201263A1 (ru) | Фармацевтическая композиция, содержащая этексилат дабигатрана | |
| MX2015017512A (es) | Compuestos 2,3-dihidrobenzofuran-5-ilicos como inhibidores de cinasas dyrk. | |
| UY33643A (es) | ?Conjugado cristalino de naloxol-PEG?. | |
| MX2015007053A (es) | Compuestos dimericos. | |
| UA112556C2 (uk) | Інсектицидні похідні 2-метоксибензамідів | |
| CY1114757T1 (el) | Παραγωγα οξαζινης και η χρηση τους στη θεραπεια νευρολογικων διαταραχων | |
| EP2524038A4 (en) | MODULATION OF TRANSFORMING A GROWTH FACTOR BETA-1 EXPRESSION | |
| DOP2006000234A (es) | Inhibidores de cinasa | |
| MX2015012600A (es) | Compuestos de tetrahidroisoquinolina-2-il-(quinazolina-4-il) metanona como inhibidores del crecimiento de células cancerígenas. | |
| SMT201300112B (it) | Sale citrato di 9E-15-(2-pirrolidin-1-il-etossi)-7,12,25-triossa-19,21,24-triaza-tetracicloÄ18.3.1.1(2,5).1(14,18)Üesacos a-1(24),2,4,9,14,16,18(26),20,22-nonaene | |
| TH148781A (th) | สารละลายสำหรับการให้ทางช่องปาก | |
| ATE523502T1 (de) | Zearalenon-makrolidderivate und ihre verwendung | |
| ZA201904033B (en) | Pharmaceutical compounds |